KINECT-HD2 Study of Oral Valbenazine for Chorea Enrolling

KINECT-HD2 Study of Oral Valbenazine for Chorea Enrolling

313598

KINECT-HD2 Study of Oral Valbenazine for Chorea Enrolling

The Huntington Study Group is seeking 30 patients to join KINECT-HD2, an open-label study of oral valbenazine capsules for chorea, or jerky involuntary movements, in Huntington’s disease, a press release states. KINECT-HD2 is an extension study of KINECT-HD (NCT04102579), a Phase 3 clinical trial that tested the safety and efficacy of valbenazine to ease chorea for 12 weeks (about three months), as compared with a placebo. The goal of the new study is to evaluate…

You must be logged in to read/download the full post.